Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Podcasts|October 28, 2026

The BioPharm Brief: A Survival Win, a Myeloma Filing, and Gene Therapy for Swallowing

Genmab’s petosemtamab plus pembrolizumab cuts the risk of death by 50% in phase 3 head and neck cancer, AbbVie submits a BLA for etentamig in relapsed or refractory multiple myeloma, and Benitec reports interim data for BB-301 gene therapy in OPMD-related dysphagia.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. We’re looking at a major survival result in head and neck cancer, a new filing in multiple myeloma, and early data for a gene therapy that targets a rare swallowing disorder.

First, Genmab’s petosemtamab plus pembrolizumab has cut the risk of death by 50% in a phase 3 trial in head and neck cancer. Petosemtamab is a bispecific antibody that targets two proteins on tumor cells, E-G-F-R and L-G-R-5. In the LiGeR-HN1 trial, patients with newly treated recurrent or metastatic PD-L1-positive disease received the combination or pembrolizumab alone. At the first interim analysis, the trial met both primary endpoints, overall survival and response rate, and the benefit held regardless of HPV status. Genmab has not yet released median survival figures and plans to present full results at a future medical meeting.

Next, AbbVie has submitted a Biologics License Application to the FDA for etentamig in adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy. Etentamig is a bispecific T-cell engager that directs the immune system against B-C-M-A, a protein found on myeloma cells. In the phase 3 CERVINO trial of 393 patients, it reduced the risk of disease progression or death by 60% compared with standard therapies, and 74% of patients responded. It is given once a month after a single step-up dose. Cytokine release syndrome occurred in about 28% of patients, and all cases were mild to moderate.

And Benitec Biopharma has reported interim data for BB-301, a gene therapy for swallowing difficulties caused by oculopharyngeal muscular dystrophy, or OPMD. This rare inherited disorder weakens the throat muscles, and nearly all patients develop trouble swallowing. BB-301 is injected directly into the throat muscles, where it silences the faulty gene and supplies a working copy. In the phase 1b/2a study, all nine treated patients met the company’s criteria for response, and no serious side effects have been reported. The study has no control group, and Benitec plans a pivotal trial for mid-2027.

That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways

  • Head and neck cancer: Petosemtamab plus pembrolizumab halved the risk of death versus pembrolizumab alone in the phase 3 LiGeR-HN1 trial.
  • Myeloma filing: AbbVie’s etentamig BLA is supported by a 60% reduction in the risk of progression or death in the phase 3 CERVINO trial.
  • Rare disease gene therapy: All nine patients treated with BB-301 met response criteria for OPMD-related dysphagia in early data.

Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.